Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
22 Mars 2022 - 7:35AM
Business Wire
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for PEA
/ SME), a Research and Development company committed to scientific
innovation for preventing and combating metabolic and
cardiovascular diseases, is strengthening its commitment to
Corporate Social Responsibility (CSR) by joining the United Nations
Global Compact and applying the ISO 26000 standard.
The United Nations Global Compact brings together businesses,
organizations, UN agencies, the professional world and civil
society around 10 universally accepted principles to build more
stable and inclusive societies. A framework for voluntary
commitment, an international reference, a platform for action and
exchange, the Global Compact is the world's largest corporate
social responsibility initiative, with more than 19,000
participants in 170 countries.
Valbiotis, through its membership, supports the 10 principles of
the United Nations Global Compact concerning the respect for human
rights, international labor standards, environmental protections
and the fight against corruption.
With this new commitment, Valbiotis expresses its will to
reinforce and integrate these principles in its long-term strategy,
its culture, its daily operations, and to advance them in its area
of influence. Valbiotis will also participate in projects advancing
the broader development goals of the United Nations, in particular
contributing to the achievement of the Sustainable Development
Goals (SDGs).
Valbiotis is already committed to SDG 3 "Good Health and
Well-Being" and SDG 9 "Industry, Innovation and Infrastructure" by
developing innovative plant-based active substances to prevent
metabolic and cardiovascular diseases or to act on early
pathological states.
During the first year of its Global Compact membership,
Valbiotis is committed to initiating action on the following
principles:
- Establishment of CSR governance, with the
creation of a CSR steering committee reporting directly to the CEO
of Valbiotis, the structuring of an ISO 26000-compliant approach
and the raising of awareness among all its employees.
- Evaluation of the impact of its activities
on the environment, and implementation of concrete actions to
contribute to SDG 13 - Measures to combat climate change.
Sébastien Peltier, CEO and Chairman of the Board of Directors
comments: "We are very proud to reinforce our commitment by joining
the United Nations Global Compact, which marks a new step in the
Company's growth and development beyond our public health mission
focused on reducing the impact that metabolic and cardiovascular
diseases can have on the millions of people at risk worldwide. It
reflects the Company's ambition, in its new dimension, to integrate
the strategy of Corporate Social Responsibility into our priority
areas of action, the commitments and objectives that will drive us
forward. We are structuring our CSR approach according to the ISO
26000 standard with the aim of eventually obtaining a label in
order to continue our growth while effecting positive change for
people and the planet.”
Two years ago, Valbiotis joined the Gaïa-Index, the French
benchmark index for Small & MidCaps in terms of ESG, a
subsidiary of EthiFinance and a player in the ESG (Environment,
Social and Governance) rating of listed French SMEs and ISEs.
Gaïa Research evaluates companies according to a benchmark of
about 170 criteria for France, divided into 4 pillars: Environment,
Social, Governance and External Stakeholders (ESG-PPE). These
criteria make it possible to assess the extent to which sustainable
development and long-term issues are taken into account in the
strategy of economic players, and to measure their progress.
About Valbiotis
Valbiotis is a Research & Development company committed to
scientific innovation for preventing and combating metabolic
diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to
revolutionize healthcare by developing a new class of health
nutrition products designed to reduce the risk of major metabolic
diseases, relying on a multi-target strategy enabled by the use of
plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the
health sector.
Created at the beginning of 2014 in La Rochelle, the Company has
forged numerous partnerships with leading academic centers. The
Company has established three sites in France – Périgny, La
Rochelle (17) and Riom (63) – and a subsidiary in Quebec City
(Canada).
Valbiotis is a member of the "BPI Excellence" network and has
been recognized as an "Innovative Company" by the BPI label.
Valbiotis has also been awarded "Young Innovative Company" status
and has received major financial support from the European Union
for its research programs via the European Regional Development
Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit:
www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851 Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
approved by the French Financial Markets Regulator (AMF) on July
27, 2021 (application number R 21-039). This document is available
on the Company’s website (www.valbiotis.com). This press release
and the information it contains do not constitute an offer to sell
or subscribe, or a solicitation to purchase or subscribe to
Valbiotis’ shares or financial securities in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220321005637/en/
Corporate communication / Valbiotis Carole ROCHER / Marc
DELAUNAY +33 5 46 28 62 58 media@valbiotis.com
Media relations / PrPa Damien MAILLARD +33 6 80 28 47 70
damien.maillard@prpa.fr
Financial communication / Actifin Stéphane RUIZ +33 1 56 88 11
14 sruiz@actifin.fr
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024